Pharmacokinetics and in vitro effects of tegaserod, a serotonin 5-hydroxytryptamine 4 (5-HT4) receptor agonist with prokinetic activity in horses

Michele L. Delco, Jorge Nieto, Athur L. Craigmill, Scott D Stanley, Jack R. Snyder

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Tegaserod, a serotonin agonist, has been shown to have prokinetic effects in horses, but pharmacokinetic information is not currently available. The pharmacokinetics and in vitro effects of tegaserod were evaluated. Tegaserod increased the contractile activity of smooth muscle preparations of the equine pelvic flexure. Pertinent pharmacokinetic parameters for a single IV and oral dose were determined. Therapeutic plasma concentrations of tegaserod were achieved with a single oral dose at 0.27 mg/kg. These findings indicate that further clinical studies are warranted to investigate potential benefits in cases of functional gastrointestinal motility disorders in horses.

Original languageEnglish (US)
Pages (from-to)77-87
Number of pages11
JournalVeterinary Therapeutics
Volume8
Issue number1
StatePublished - Mar 2007

ASJC Scopus subject areas

  • veterinary(all)
  • Animal Science and Zoology

Fingerprint Dive into the research topics of 'Pharmacokinetics and in vitro effects of tegaserod, a serotonin 5-hydroxytryptamine 4 (5-HT<sub>4</sub>) receptor agonist with prokinetic activity in horses'. Together they form a unique fingerprint.

  • Cite this